What are the benefits of early anticoagulation therapy in patients with acute ischemic stroke and atrial fibrillation?
Early anticoagulation therapy in patients with acute ischemic stroke and atrial fibrillation has been shown to reduce the risk of recurrent stroke, improve stroke outcomes, and reduce the risk of cerebral hemorrhage. Studies have shown that early anticoagulation therapy was associated with improved functional outcome at 3 months (Paciaroni et al., 2015; Abdul-Rahim et al., 2015; Kernan et al., 2014). Additionally, early anticoagulation therapy has been associated with a decreased risk of early recurrence and cerebral bleeding (Paciaroni et al., 2008; 2015; Hallevi et al., 2015). Furthermore, a population based stroke registry (LuSSt) reported that early anticoagulation therapy was associated with improved stroke survival (Palm et al., 2014). Thus, it can be concluded that early anticoagulation therapy in patients with acute ischemic stroke and atrial fibrillation provides benefit in terms of improved outcomes and reduced risks. 